Ruddy Jean Marie, Yarbrough William, Brothers Thomas, Robison Jacob, Elliott Bruce
Division of Vascular Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.
South Med J. 2008 Nov;101(11):1113-116. doi: 10.1097/SMJ.0b013e318179266c.
The optimal treatment for patients requiring intervention for coronary artery disease (CAD) and concomitant large or symptomatic abdominal aortic aneurysm (AAA) remains problematic.
Retrospective analysis was performed of 32 patients with symptomatic or large (> cm) AAA along with significant CAD treated over the past fifteen years at a university hospital.
Mean AAA diameter was 6.6 cm. CAD involved 3 or more vessels in all patients. Fifteen patients underwent staged coronary artery bypass grafting (CABG) followed by open AAA repair, with two (13%) dying as a result of aneurysm rupture in the early postoperative period. No major complications were encountered among five patients receiving staged coronary angioplasty before open AAA repair and two patients undergoing staged CABG followed by endovascular aneurysm repair. Ten patients underwent concomitant CABG and AAA repair, with a single intraoperative death (10%). No differences in morbidity were observed among patients undergoing concomitant procedures as compared with those subjected to staged procedures.
Minimally invasive interventions for coronary revascularization and aortic aneurysm repair appear to be safe and effective options in properly selected high-risk patients. While optimal management must be individualized, these data suggest that either staged or concomitant CABG and AAA repair may be viable options when minimally invasive interventions are not feasible.
对于需要对冠状动脉疾病(CAD)和伴有大型或有症状的腹主动脉瘤(AAA)进行干预的患者,最佳治疗方案仍存在问题。
对一所大学医院在过去15年中治疗的32例有症状或大型(> cm)AAA且伴有严重CAD的患者进行回顾性分析。
AAA平均直径为6.6 cm。所有患者的CAD均累及3支或更多血管。15例患者接受了分期冠状动脉旁路移植术(CABG),随后进行开放性AAA修复,其中2例(13%)在术后早期因动脉瘤破裂死亡。在5例接受开放性AAA修复前分期冠状动脉成形术的患者和2例接受分期CABG随后进行血管内动脉瘤修复的患者中未遇到重大并发症。10例患者同时进行了CABG和AAA修复,术中死亡1例(10%)。与接受分期手术的患者相比,接受同期手术的患者在发病率方面未观察到差异。
对于经过适当选择的高危患者,冠状动脉血运重建和主动脉瘤修复的微创干预似乎是安全有效的选择。虽然最佳管理必须个体化,但这些数据表明,当微创干预不可行时,分期或同期CABG和AAA修复可能是可行的选择。